Both naringenin and 1D11 treatments significantly reduced the percentage of CD4+CD25+Foxp3+ and CD103+CD4+Foxp3+ cells in the lungs and spleens, respectively, of 4T1/TGF-β1 tumor-bearing mice (P <0.05) (Fig. 3a, b). Here, TGFB1 is linked to neoplasm.